Hepatic Tumor Burden Can Be Reduced Rapidly and Effectively by Trans-Arterial Embolization Combined with Systemic Therapy in Patients with Neuroendocrine Tumor Liver Metastasis (NETLM)

#2040

Introduction: The main tumor burden of patients with neuroendocrine tumor liver metastasis is comprised by hepatic lesions.

Aim(s): To evaluate the effect of Trans-Arterial Embolization (TAE) on reducing tumor burden in liver for NETLM patients.

Materials and methods: Nineteen pathologically proved G2 NET patients with type III liver metastasis who underwent TAE during September 2014 and July 2017 were enrolled. Primary site was pancreas in 14/19 patients, rectum in 2/19 patients and others in 3/19 patients. All patients received combined systemic treatment, including 16 Octreotide, 6 Sunitinib, 5 Captem and 5 Everolimus. PVA with diameter ranging 100-300μm were used as embolization agent in all TAE procedures. CT scans were run before and after TAE (1, 3, 6 months) and treatment response of target lesions were assessed according to mRECIST.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Liu Y

Authors: Liu Y, Wang Y, Lian F, Shen L, Chen L,

Keywords: intervention, TAE, liver metastasis,

Hepatic Tumor Burden Can be Reduced Rapidly and Effectively by Trans-Arterial Embolization Combined with Systemic Therapy in Patients with Neuroendocrine Tumor Liver Metastasis (NETLM)

#2041

Introduction: The main tumor burden of patients with neuroendocrine tumor liver metastasis is comprised by hepatic lesions.

Aim(s): To evaluate the effect of Trans-Arterial Embolization (TAE) combined with systemic therapy on reducing tumor burden in liver for NETLM patients.

Materials and methods: Nineteen pathologically proved G2 NET patients with type III liver metastasis who underwent TAE during September 2014 and July 2017 were enrolled. Primary site was pancreas in 14/19 patients, rectum in 2/19 patients and others in 3/19 patients. All patients received combined systemic treatment, including 16 Octreotide, 6 Sunitinib, 5 Captem and 5 Everolimus. PVA with diameter ranging 100-300μm were used as embolization agent in all TAE procedures. CT scans were run before and after TAE (1, 3, 6 months) and treatment response of target lesions were assessed according to mRECIST.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Liu Y

Authors: Liu Y, Wang Y, Lian F, Shen L, Chen L,

Keywords: intervention, TAE, liver metastasis,